NCT06182072View on ClinicalTrials.gov

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

PHASE1RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 14, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
DRUG

ProAgio Dose Levels (DL) 1,2,3,4

ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.

DRUG

Gemcitabine, nab paclitaxel

ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.

Trial Locations (1)

35294

RECRUITING

O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham

All Listed Sponsors
collaborator

University of Alabama at Birmingham

OTHER

collaborator

Georgia State University

OTHER

lead

ProDa BioTech, LLC

INDUSTRY